These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 12807436)
1. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. Lakso M; Vartiainen S; Moilanen AM; Sirviö J; Thomas JH; Nass R; Blakely RD; Wong G J Neurochem; 2003 Jul; 86(1):165-72. PubMed ID: 12807436 [TBL] [Abstract][Full Text] [Related]
2. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443 [TBL] [Abstract][Full Text] [Related]
3. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Thiruchelvam MJ; Powers JM; Cory-Slechta DA; Richfield EK Eur J Neurosci; 2004 Feb; 19(4):845-54. PubMed ID: 15009131 [TBL] [Abstract][Full Text] [Related]
4. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Gispert S; Del Turco D; Garrett L; Chen A; Bernard DJ; Hamm-Clement J; Korf HW; Deller T; Braak H; Auburger G; Nussbaum RL Mol Cell Neurosci; 2003 Oct; 24(2):419-29. PubMed ID: 14572463 [TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Chen KS; Menezes K; Rodgers JB; O'Hara DM; Tran N; Fujisawa K; Ishikura S; Khodaei S; Chau H; Cranston A; Kapadia M; Pawar G; Ping S; Krizus A; Lacoste A; Spangler S; Visanji NP; Marras C; Majbour NK; El-Agnaf OMA; Lozano AM; Culotti J; Suo S; Ryu WS; Kalia SK; Kalia LV Mol Neurodegener; 2021 Nov; 16(1):77. PubMed ID: 34772429 [TBL] [Abstract][Full Text] [Related]
6. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. Haywood AF; Staveley BE BMC Neurosci; 2004 Apr; 5():14. PubMed ID: 15090075 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678 [TBL] [Abstract][Full Text] [Related]
9. Application of a C. elegans dopamine neuron degeneration assay for the validation of potential Parkinson's disease genes. Berkowitz LA; Hamamichi S; Knight AL; Harrington AJ; Caldwell GA; Caldwell KA J Vis Exp; 2008 Jul; (17):. PubMed ID: 19066512 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. Dong Z; Ferger B; Feldon J; Büeler H J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578 [TBL] [Abstract][Full Text] [Related]
11. Neuropathology in mice expressing human alpha-synuclein. van der Putten H; Wiederhold KH; Probst A; Barbieri S; Mistl C; Danner S; Kauffmann S; Hofele K; Spooren WP; Ruegg MA; Lin S; Caroni P; Sommer B; Tolnay M; Bilbe G J Neurosci; 2000 Aug; 20(16):6021-9. PubMed ID: 10934251 [TBL] [Abstract][Full Text] [Related]
12. TDP-1/TDP-43 potentiates human α-Synuclein (HASN) neurodegeneration in Caenorhabditis elegans. Shen L; Wang C; Chen L; Leung KL; Lo E; Lakso M; Wong G Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165876. PubMed ID: 32531261 [TBL] [Abstract][Full Text] [Related]
13. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Giasson BI; Duda JE; Quinn SM; Zhang B; Trojanowski JQ; Lee VM Neuron; 2002 May; 34(4):521-33. PubMed ID: 12062037 [TBL] [Abstract][Full Text] [Related]
14. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577 [TBL] [Abstract][Full Text] [Related]
15. A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. Kuwahara T; Koyama A; Koyama S; Yoshina S; Ren CH; Kato T; Mitani S; Iwatsubo T Hum Mol Genet; 2008 Oct; 17(19):2997-3009. PubMed ID: 18617532 [TBL] [Abstract][Full Text] [Related]
16. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208 [TBL] [Abstract][Full Text] [Related]
17. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons. Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688 [TBL] [Abstract][Full Text] [Related]
18. Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans. Cao P; Yuan Y; Pehek EA; Moise AR; Huang Y; Palczewski K; Feng Z PLoS One; 2010 Feb; 5(2):e9312. PubMed ID: 20174477 [TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. Manning-Bog AB; McCormack AL; Purisai MG; Bolin LM; Di Monte DA J Neurosci; 2003 Apr; 23(8):3095-9. PubMed ID: 12716914 [TBL] [Abstract][Full Text] [Related]
20. Increased lifespan in transgenic Caenorhabditis elegans overexpressing human alpha-synuclein. Vartiainen S; Aarnio V; Lakso M; Wong G Exp Gerontol; 2006 Sep; 41(9):871-6. PubMed ID: 16782295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]